immuno-oncology weekly, page-20

Thanks Taichi, I couldn't it to work.......

Immutep have combos that only "efti" can make work, some iniated

by itself, some by the big players.....Interesting Immutep targeted others

firstly by necessity pre T/O days with Immutep SA for cash flow etc with

GSK and Novartis some 7 or 8 years ago.....I note, those partnerships are still

continuing and progressing in phases....More interesting and potentially

more profitable is the undoubted Merck interest and it seems they have

convinced Pfizer of it's potential.....

I didn't mention EOC in China (pre T/O) and Cytlimic in Japan,(post T/O)..

News about to flow....I also see they are taking Dr Atkinson from

Greenslopes hospital with them to present Tact-Mel data on the

world stage....I find that encouraging....